🚀 VC round data is live in beta, check it out!
Genetic Technologies Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genetic Technologies and similar public comparables like Mersana Therapeutics, Prestige Biologics, Vaxcell-Bio, Sangamo Therapeutics and more.
Genetic Technologies Overview
About Genetic Technologies
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Founded
1987
HQ
Employees
58
Website
Sectors
Financials (FY)
EV
$145M
Genetic Technologies Financials
Genetic Technologies reported last fiscal year revenue of $5M and negative EBITDA of ($8M).
In the same fiscal year, Genetic Technologies generated $3M in gross profit, ($8M) in EBITDA losses, and had net loss of ($8M).
Revenue (LTM)
Genetic Technologies P&L
In the most recent fiscal year, Genetic Technologies reported revenue of $5M and EBITDA of ($8M).
Genetic Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $3M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 51% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (149%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (159%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($8M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (157%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Genetic Technologies Stock Performance
Genetic Technologies has current market cap of $145M, and enterprise value of $145M.
Market Cap Evolution
Genetic Technologies' stock price is $1.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $145M | $145M | — | XXX | XXX | XXX | $-0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenetic Technologies Valuation Multiples
Genetic Technologies trades at 27.5x EV/Revenue multiple, and (18.5x) EV/EBITDA.
EV / Revenue (LTM)
Genetic Technologies Financial Valuation Multiples
As of March 29, 2026, Genetic Technologies has market cap of $145M and EV of $145M.
Equity research analysts estimate Genetic Technologies' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genetic Technologies has a P/E ratio of (17.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $145M | XXX | $145M | XXX | XXX | XXX |
| EV (current) | $145M | XXX | $145M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 27.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (18.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (17.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 54.0x | XXX | XXX | XXX |
| P/E | — | XXX | (17.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (21.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genetic Technologies Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Genetic Technologies Margins & Growth Rates
Genetic Technologies' revenue in the last fiscal year declined by (6%).
Genetic Technologies Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (149%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 1% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 133% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 210% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Genetic Technologies Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mersana Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Prestige Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vaxcell-Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Sangamo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Corbus Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genetic Technologies M&A Activity
Genetic Technologies acquired XXX companies to date.
Last acquisition by Genetic Technologies was on XXXXXXXX, XXXXX. Genetic Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Genetic Technologies
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGenetic Technologies Investment Activity
Genetic Technologies invested in XXX companies to date.
Genetic Technologies made its latest investment on XXXXXXXX, XXXXX. Genetic Technologies invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Genetic Technologies
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genetic Technologies
| When was Genetic Technologies founded? | Genetic Technologies was founded in 1987. |
| Where is Genetic Technologies headquartered? | Genetic Technologies is headquartered in Australia. |
| How many employees does Genetic Technologies have? | As of today, Genetic Technologies has over 58 employees. |
| Is Genetic Technologies publicly listed? | Yes, Genetic Technologies is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Genetic Technologies? | Genetic Technologies trades under GNTLF ticker. |
| When did Genetic Technologies go public? | Genetic Technologies went public in 2002. |
| Who are competitors of Genetic Technologies? | Genetic Technologies main competitors are Mersana Therapeutics, Prestige Biologics, Vaxcell-Bio, Sangamo Therapeutics. |
| What is the current market cap of Genetic Technologies? | Genetic Technologies' current market cap is $145M. |
| What is the current revenue of Genetic Technologies? | Genetic Technologies' last fiscal year revenue is $5M. |
| What is the current EV/Revenue multiple of Genetic Technologies? | Current revenue multiple of Genetic Technologies is 27.5x. |
| Is Genetic Technologies profitable? | No, Genetic Technologies is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.